Davids versus Goliaths: Pharma and academia threats to individual scientists and clinicians

Autor: Charles L. Bennett, Nancy Olivieri, Shamia Hoque, David Aboulafia, Anne Ventrone, Courtney Lubaczewski, Betty Dong, Benjamin Schooley, Bartlett J. Witherspoon, Paul S. Ray, William J. Hrushesky, John Restaino, Henrik S. Thomsen, Dennis Mangano, Christina Mora-Mangano, June M. McKoy, Martin Schoen, Kevin Knopf, Linda Martin, Steven Rosen

Publikováno v: The Journal of Scientific Practice and Integrity (2022)

# Background We previously described experiences of clinicians who published adverse drug reaction reports. We now report on threats and intimidations leveled against clinicians and scientists who received publicly documented threats after communica

Externí odkaz: https://doaj.org/article/c58a1f473a3e44cfa3fb8a9e0941656a

Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions.

Autor: Charles L Bennett, Benjamin Schooley, Matthew A Taylor, Bartlett J Witherspoon, Ashley Godwin, Jayanth Vemula, Henry C Ausdenmoore, Oliver Sartor, Y Tony Yang, James O Armitage, William J Hrushesky, John Restaino, Henrik S Thomsen, Paul R Yarnold, Terence Young, Kevin B Knopf, Brian Chen

Publikováno v: PLoS ONE, Vol 14, Iss 7, p e0219521 (2019)

Oncology-associated adverse drug/device reactions can be fatal. Some clinicians who treat single patients with severe oncology-associated toxicities have researched case series and published this information. We investigated motivations and experienc

Externí odkaz: https://doaj.org/article/cd483feedc194083bb6e684e36fe4e63

Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)

Autor: Shamia Hoque, Kevin B. Knopf, Marc L. Fishman, Steven D. Rosen, Courtney Lubaczewski, Paul Ray, Paul R. Yarnold, Oliver Sartor, Henry C. Ausdenmoore, Matthew A. Taylor, Robert E. Marx, Benjamin Schooley, Martin W. Schoen, Y. Tony Yang, Nancy F. Olivieri, David M. Aboulafia, Jay Vemula, William J. M. Hrushesky, Juan Aldaco, Salvatore L. Ruggiero, John Restaino, Henrik S. Thomsen, Anne Ventrone, Linda Martin, June M. McKoy, William K. Smith, Georgne Herring, Ashley Caitlin Godwin, Cesar A. Migliorati, Chadi Nabhan, Charles L. Bennett, Andrew C Bennett, Bartlett J. Witherspoon, Kenneth R. Carson

Publikováno v: EClinicalMedicine
Bennett, C L, Hoque, S, Olivieri, N, Taylor, M A, Aboulafia, D, Lubaczewski, C, Bennett, A C, Vemula, J, Schooley, B, Witherspoon, B J, Godwin, A C, Ray, P S, Yarnold, P R, Ausdenmoore, H C, Fishman, M, Herring, G, Ventrone, A, Aldaco, J, Hrushesky, W J, Restaino, J, Thomsen, H S, Marx, R, Migliorati, C, Ruggiero, S, Nabhan, C, Carson, K R, McKoy, J M, Yang, Y T, Schoen, M W, Knopf, K, Martin, L, Sartor, O, Rosen, S & Smith, W K 2021, ' Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019) : A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) ', EClinicalMedicine, vol. 31, 100693 . https://doi.org/10.1016/j.eclinm.2020.100693
EClinicalMedicine, Vol 31, Iss, Pp 100693-(2021)

Background: Adverse drug/device reactions (ADRs) can result in severe patient harm. We define very serious ADRs as being associated with severe toxicity, as measured on the Common Toxicity Criteria Adverse Events (CTCAE)) scale, following use of drug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8fdef53ceebcd51c405194512b0ec7b
https://pubmed.ncbi.nlm.nih.gov/33554084

Caveat medicus:Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions

Autor: Bartlett J. Witherspoon, Jayanth Vemula, Paul R. Yarnold, Henry C. Ausdenmoore, Oliver Sartor, William J. M. Hrushesky, Brian Chen, Ashley Caitlin Godwin, Matthew A. Taylor, Benjamin Schooley, Kevin B. Knopf, Y. Tony Yang, John Restaino, Henrik S. Thomsen, Charles L. Bennett, Terence Young, James O. Armitage

Publikováno v: Bennett, C L, Schooley, B, Taylor, M A, Witherspoon, B J, Godwin, A, Vemula, J, Ausdenmoore, H C, Sartor, O, Tony Yang, Y, Armitage, J O, Hrushesky, W J, Restaino, J, Thomsen, H S, Yarnold, P R, Young, T, Knopf, K B & Chen, B 2019, ' Caveat medicus : Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions ', PLoS ONE, vol. 14, no. 7, e0219521 . https://doi.org/10.1371/journal.pone.0219521
PLoS ONE
PLoS ONE, Vol 14, Iss 7, p e0219521 (2019)

Oncology-associated adverse drug/device reactions can be fatal. Some clinicians who treat single patients with severe oncology-associated toxicities have researched case series and published this information. We investigated motivations and experienc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::015826326591894854c5eea81cf1a103
https://curis.ku.dk/portal/da/publications/caveat-medicus(69ed2c01-952f-49f1-bfce-88975f200e65).html

Key Elements in Adverse Drug Reactions Safety Signals: Application of Legal Strategies

Autor: John Restaino, Brian Chen, Elizabeth Chika Tippett

Publikováno v: Cancer Treatment and Research ISBN: 9783319438948

Adverse drug reactions, or unintended and harmful outcomes related to the administration of a pharmaceutical product, are a major public health concern, particularly for cancer patients. If counted as a separate cause of death, adverse drug reactions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69e6ec5d7c8237f1cf950a30c2eb2492
https://doi.org/10.1007/978-3-319-43896-2_4